Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBX Vape Free is an oral thin film (dissolvable strip) developed by Redwood Scientific Technologies for vaping cessation and nicotine dependence. It utilizes cytisine, a plant-derived alkaloid from the golden rain tree (*Cytisus laburnum*), as its active ingredient. Cytisine acts as a partial agonist at nicotinic acetylcholine receptors (nAChRs), specifically targeting the same receptors as nicotine to alleviate cravings and withdrawal symptoms with a lower risk of addiction. The product is designed as a fast-acting, sublingual delivery system and is intended for commercialization as a homeopathic over-the-counter (OTC) drug product following clinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TBX Vape Free.